Fragmentomic Liquid Biopsy: Revolutionizing Breast Cancer Management
Achieving 95% Sensitivity in Early Detection, Molecular Subtyping, and Lymph Node Assessment
This landmark multicenter study introduces TuFEst, an AI-driven liquid biopsy model leveraging genome-wide cell-free DNA (cfDNA) fragmentomic features. TuFEst delivers unprecedented accuracy in early breast cancer detection, molecular subtyping, and lymph node status prediction, addressing critical unmet needs in global oncology.
Accelerating Oncology with Precision AI
Leverage cutting-edge AI to transform breast cancer diagnosis and management. Our solution empowers earlier detection, personalized treatment, and optimized patient outcomes.
0%
Early Cancer Detection Sensitivity
0%
Early Cancer Detection Specificity
0%
Metastatic Subtyping Accuracy
0%
Negative LN Prediction (NPV)
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
The TuFEst model leverages advanced machine learning to analyze cfDNA fragmentomic patterns, providing a multi-faceted approach to breast cancer diagnosis and management. This integrated strategy offers high sensitivity and specificity, addressing critical limitations of conventional methods.
96.2%
Accuracy for Imaging False-Negatives (BI-RADS 3)
Enterprise Process Flow
cfDNA Extraction
→
Low-Pass WGS
→
Fragmentomic Feature Extraction
→
AI Model (TuFEst) Training
→
Early BC Detection & Classification
The TuFEst model leverages advanced machine learning to analyze cfDNA fragmentomic patterns, providing a multi-faceted approach to breast cancer diagnosis and management. This integrated strategy offers high sensitivity and specificity, addressing critical limitations of conventional methods.
| Feature | TuFEst-MS | Conventional Methods |
|---|---|---|
| Methodology | Genome-wide cfDNA fragmentation patterns, AI-driven machine learning | Tissue biopsy, IHC/FISH, gene expression panels |
| Invasiveness | Non-invasive (blood test) | Invasive (biopsy) |
| Turnaround Time | Rapid (e.g., 72h for results) | Variable (days to weeks for pathology) |
| Accessibility | High (less infrastructure needed) | Limited (biopsy expertise, specialized labs) |
| Discordance Handling | Accounts for tumor heterogeneity | Prone to spatial/temporal discordance |
| Actionability | Supports treatment decisions & trial eligibility | Supports treatment decisions |
The TuFEst model leverages advanced machine learning to analyze cfDNA fragmentomic patterns, providing a multi-faceted approach to breast cancer diagnosis and management. This integrated strategy offers high sensitivity and specificity, addressing critical limitations of conventional methods.
Precision LN Staging for CNO Patients
TuFEst-LN demonstrated a 97.6% negative predictive value in imaging-discordant cases, enabling confident surgical de-escalation for node-negative patients and targeted systemic therapy for those at higher risk. This is critical for optimizing adjuvant treatment and avoiding unnecessary surgeries.
The TuFEst model leverages advanced machine learning to analyze cfDNA fragmentomic patterns, providing a multi-faceted approach to breast cancer diagnosis and management. This integrated strategy offers high sensitivity and specificity, addressing critical limitations of conventional methods.
2.8
NES for Inflammatory Response Pathways (High Cancer Score)
Calculate Your Potential ROI
Estimate the financial and operational benefits of integrating AI-driven insights into your enterprise. Adjust parameters to reflect your organization's specifics.
Estimated Annual Savings
$0
Annual Hours Reclaimed
0
Your AI Implementation Roadmap
Implementing an AI-driven liquid biopsy platform like TuFEst requires a strategic, phased approach to ensure seamless integration into existing healthcare workflows and maximize clinical impact.
Phase 1: Pilot Program & Clinical Validation
Establish a pilot program in key oncology centers for prospective validation of TuFEst in diverse patient cohorts, including high-risk and imaging-discordant cases. Focus on data integration with existing EMR systems.
Phase 2: Regulatory Submission & Guideline Integration
Prepare and submit regulatory dossiers for clinical approval. Work with national and regional medical societies to integrate TuFEst into breast cancer screening and management guidelines.
Phase 3: Scaled Deployment & Healthcare Provider Training
Expand TuFEst deployment across a network of hospitals and primary care facilities. Develop comprehensive training programs for oncologists, radiologists, and general practitioners on test interpretation and clinical utility.
Phase 4: Real-World Evidence & Value-Based Care
Continuously collect real-world evidence to demonstrate long-term patient outcomes and cost-effectiveness. Explore value-based care models where TuFEst informs personalized treatment pathways.
Ready to Transform Your Oncology Practice?
Schedule a personalized consultation with our AI specialists to explore how TuFEst can be integrated into your clinical workflow, enhancing early detection and precision medicine.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat